MAPT and Alzheimer disease: In addition to the emerging role of plasma Aβ as a biomarker for AD, plasma measurements of tau phosphorylated at threonine 231 (p-tau231), p-tau181 and p-tau217 have also shown diagnostic potential for the disease [13,14,15].